替吉奥治疗晚期乳腺癌的研究进展

郑婷; 钱其军

doi:10.3969/j.issn.1006-0111.2015.06.021

替吉奥治疗晚期乳腺癌的研究进展

doi: 10.3969/j.issn.1006-0111.2015.06.021

郑婷¹,
钱其军^2,

1.
福建医科大学第一临床医学院, 福建福州 350108;第二军医大学附属东方肝胆外科医院生物治疗科、病毒基因治疗实验室, 上海 200438
2.
第二军医大学附属东方肝胆外科医院生物治疗科、病毒基因治疗实验室, 上海 200438

基金项目: 国家科技重大专项(No.2013ZX10002-010-007)

Progress on S-1 in the treatment of advanced breast cancer

ZHENG Ting¹,
QIAN Qijun^2
,

1.
First Clinical Medical College, Fujian Medical University, Fuzhou 350108, China;Laboratory of Gene and Viral Therapy, Department of Biotherapy, Eastern Hepatobiliary Surgery Hospital Affiliated to Second Military Medical University, Shanghai 200438, China
2.
Laboratory of Gene and Viral Therapy, Department of Biotherapy, Eastern Hepatobiliary Surgery Hospital Affiliated to Second Military Medical University, Shanghai 200438, China

摘要: 替吉奥(S-1)是第三代氟尿嘧啶衍生物的口服抗癌剂,毒副作用小、疗效确切、给药方便。在大量的临床试验及不断的临床应用中,其展示出对晚期乳腺癌(advanced breast cancer,ABC)治疗的良好效果,将来有望成为乳腺癌治疗的一线化疗药物。
- 替吉奥(S-1) /
- 晚期乳腺癌 /
- 化疗药物
Abstract: S-1 is the third generation of fluorouracil derivative anti-cancer agent with small side effects, efficacy, and drug delivery is convenient.In a large number of clinical trials and continuous clinical application, it showed the good effect for the treatment of advanced breast cancer, which was expected to become the first-line chemotherapy drug for breast cancer treatment in the future.
- S-1 /
- advanced breast cancer /
- chemotherapy drug

[1]	Jemal A,Bray F,Center MM,et al.Global cancer statistics[J].CA Cancer J Clin,2011,61(2):69-90.
[2]	邬晓敏,章烨,朱为民,等.培美曲塞联合顺铂治疗晚期乳腺癌的疗效观察[J].中国癌症杂志,2011,21(2):159-160.
[3]	汪进良,焦顺昌.替吉奥用于非小细胞肺癌治疗的研究及展望[J].中华医学杂志,2010,90(36):2582-2585.
[4]	Muro K,Boku N,Shimada Y,et al.Irinotecan plus S-1(IRIS)versus fluorouracil and folinic acid plus irinotecan(FOLFIRI) as second-line chemotherapy for metastatic colorectal cancer:a randomised phase 2/3 non-inferiority study(FIRIS study)[J].Lancet Oncol,2010,11(9):853-860.
[5]	Ueno H,Okusaka T,Furuse J,et al.Multicenter phase Ⅱ study of gemcitabine and S-1 combination therapy(GSTherapy) in patients with metastatic pancreatic cancer[J].Jpn J Clin Oncol,2011,41(8):953-958.
[6]	Saito Y,Oshitanai R,Terao M,et al.Post-marketing safety evaluation of S-1 in patients withinoperable or recurrent breast cancer: especially in patients treated with S-1 1 trastuzumab[J].Jpn J Clin Oncol, 2011,41(9):1051-1058.
[7]	Yamamoto Y, Nishimura R, Tanigawa T,et al.Efficacy and safety of TS-1 monotherapy for advanced/metastatic breast cancer-an observational study by the Kumamoto Breast Cancer Cooperative Group(KBCCG) [J].GanTo Kagaku Ryoho,2014,41(10):1221-1225.
[8]	马培奇.抗肿瘤新药替吉奥钾研究进展[J].中国医药导刊,2007,9(6):499-502.
[9]	Malet-Martino M,Martino R. Clinical studies of three oralprodrugs of 5-fluorouracil(capecitabine,UFT,S-1):a review[J].Oncologist,2002,7(4):288-323.
[10]	Ito Y,Osaki Y,Tokudome N,et al.Efficacy of S-1 in heavilypretreated patients with metastatic breast cancer:cross-resistance to capecitabine[J].Breast Cancer,2009,16(2):126.
[11]	Saeki T,Takashima S,Sano M,et al.Aphase Ⅱ study of S-1 in patients with metastatic breast cancer-a Japanese trial by the S-1 Cooperative Study Group, Breast Cancer Working Group[J].Breast Cancer,2004,11(2):194-202.
[12]	Shien T,Shimizu C,Akashi-Tanakal S,et al.Clinical efficacy of S-1 in pretreated metastatic breast cancer patients[J].Jpn J Clin Oncol,2008,38(3):172-175.
[13]	Vici P,Giotta F,Di Lauro L,et al.A multicenter phase Ⅱ randomized trial of docetaxel/gemcitabine versus docetaxel/capecitabine as first-line treatment for advanced breast cancer:a gruppo oncologico Italia meridionale study[J].Oncology,201l,81(3-4):230-236.
[14]	Lee JL,Kang YK,Kang HJ,et al.A randomised multicentre phaseⅡ trial of capecitabine vs S-1 as first-line treatment in elderly patients with metastatic or recurrent unresectable gastric cancer[J].Br J Cancer,2008,99(4):584-590.
[15]	Yamamoto D,Iwase S,Yoshida H,et al.Efficacy of S-1 in patients with capecitabine-resistantbreast cancer-Japan Breast Cancer Research Network (JBCRN) 04-1 trial[J].Anticancer Res,2010,30(9): 3827-3831.
[16]	Mukai H, Takashima T, HozumiY,et al.Randomized study of taxane versus TS-1 in women with metastatic or recurrent breast cancer (SELECT BC) [J].Jpn J Clin Oncol, 2010,40(8):811-814.
[17]	Nohara T,Iwamoto M,Sumiyoshi K, et al.Examination of the clinical usefulness of TS-1 in locally recurrent breast cancer[J]. Oncol Let,2010,1(4): 669-672.
[18]	Yamamoto Y, Nishimura R, Tanigawa T,et al.Efficacy and safety of TS-1 monotherapy for advanced/metastatic breast cancer-an observational study by the Kumamoto Breast Cancer Cooperative Group(KBCCG)].GanTo Kagaku Ryoho. 2014,41(10):1221-1225.
[19]	Kobayashi Y, Kadoya T, Kanno E,et al.A resected case of complete response after treatment with S-1 for recurrent squamous cell carcinoma component of the breast[J].GanTo Kagaku Ryoho,2012,39(9):1403-1406.
[20]	Tazawa K, Tsuchiya Y, Shinbo M,et al.Effective chemotherapy with S-1 alone in a patient with lung metastases of breast cancer[J].GanTo Kagaku Ryoho, 2011,38(3):423-425.
[21]	Yoshida H, Yamamoto D, Kanematsu S,et al.A case of multi-drug resistant breast cancer with liver metastasis treated effectively by S-1 monotherapy[J].GanTo Kagaku Ryoho,2010,37(13):2901-2903.
[22]	Takeyama H, Kyoda S, Yamashita A,et al.A case of repeated bone metastases of breast carcinoma successfully treated by S-1 chemotherapy[J].GanTo Kagaku Ryoho,2011,38(11):1873-1875.
[23]	Mori T, Yoshimura G, Ito D,et al.Three cases effectively treated with S-1 therapy for liver metastasis of breast cancer in long term[J].GanTo Kagaku Ryoho,2011,38(9):1495-1498.
[24]	Kubo H, Kijima D, Tada K,et al.A case of anthracycline- and taxane-resistant recurrent advanced breast cancer successfully treated with S-1 monotherapy[J].GanTo Kagaku Ryoho,2010,37(7):1325-1327.
[25]	Kato M, Kitayama J, Yamaguchi H,et al.Three cases of metastatic breast cancer effectively treated with S-1 therapy[J].GanTo Kagaku Ryoho,2010,37(5):903-906.
[26]	Aoyagi H, Kaneko J, Makinose T,et al.A case of stage IV breast cancer responding to S-1 therapy after FEC and PTX therapies[J].GanTo Kagaku Ryoho,2009,36(12):2474-2476.
[27]	Takashima T, Nakayama T, Yoshidome K,et al.Phase Ⅱ study of s-1 in combination with trastuzumab for HER2-positive metastatic breast cancer[J].Anticancer Res, 201434: 3583-3588 .
[28]	Ishida K.A case of recurrent breast cancer with liver metastases showing good response to combination therapy with S-1plus trastuzumab[J].GanTo Kagaku Ryoho,2013,40(10):1385-1387.
[29]	Nakayama T, Morita S, Takashima T,et al.Phase Ⅰ study of S-1 in combination with trastuzumab for HER2-positive metastatic breast cancer[J].Anticancer Res,2011,31(9):3035-3039.
[30]	Tokugawa T, Kobayashi A, Okubo K,et al.A patient with multiple skin metastases from breast cancer responding to S-1 effectively under treatment with trastuzumab[J].GanTo Kagaku Ryoho,2009,36(4):679-682.

[1]	岳春华, 贲永光, 王海桥. 基于NLRP1炎症小体探讨百合知母汤抗抑郁的作用机制 . 药学实践与服务, 2024, 42(8): 325-333. doi: 10.12206/j.issn.2097-2024.202401033
[2]	李想, 陆鸿远, 张明玉, 高欢, 姚东, 许子华. 米格列醇激活UCP1介导棕色脂肪对冷暴露小鼠损伤的研究 . 药学实践与服务, 2024, 42(): 1-6. doi: 10.12206/j.issn.2097-2024.202404005
[3]	凯丽比努尔·奥布力艾散, 李倩, 谢志, 贾文彦, 尹东锋. 星点设计-效应面法优化仑伐替尼混合胶束的制备工艺 . 药学实践与服务, 2024, 42(): 1-8. doi: 10.12206/j.issn.2097-2024.202403019
[4]	张艺昕, 关欣怡, 王博宁, 闻俊, 洪战英. 二氢吡啶类钙离子拮抗药物手性分析及其立体选择性药动学研究进展 . 药学实践与服务, 2024, 42(8): 319-324. doi: 10.12206/j.issn.2097-2024.202308062
[5]	夏哲炜, 曾垣烨, 朱海菲, 李育, 陈啸飞. 核磁共振磷谱法测定磷酸氢钙咀嚼片中药物含量 . 药学实践与服务, 2024, 42(9): 399-401, 406. doi: 10.12206/j.issn.2097-2024.202404063
[6]	孙丹倪, 黄勇, 张嘉宝, 王培. 代谢相关脂肪性肝病的无创诊断与药物治疗 . 药学实践与服务, 2024, 42(10): 411-418. doi: 10.12206/j.issn.2097-2024.202403049
[7]	陈怡君, 王卓, 何苗, 张宇, 田泾. 泌尿系统碎石术抗菌药物预防使用合理管控实践 . 药学实践与服务, 2024, 42(): 1-5. doi: 10.12206/j.issn.2097-2024.202402034
[8]	张元林, 宋凯, 孙蕊, 舒飞, 舒丽芯, 杨樟卫. 基于真实世界数据的药物利用研究综述 . 药学实践与服务, 2024, 42(6): 238-243. doi: 10.12206/j.issn.2097-2024.202312010
[9]	崔晓林, 付晓菲, 杜艳红, 刘娟, 朱茜, 刘子祺. 临床药师参与吉瑞替尼致QTc间期延长的病例分析 . 药学实践与服务, 2024, 42(6): 263-266. doi: 10.12206/j.issn.2097-2024.202309050
[10]	冯志惠, 邓仪卿, 叶冰, 安培, 张宏, 张海军. 雀梅藤石油醚提取物诱导三阴性乳腺癌细胞凋亡的实验研究 . 药学实践与服务, 2024, 42(6): 253-259. doi: 10.12206/j.issn.2097-2024.202311055
[11]	宋雨桐, 夏德润, 顾珩, 唐少文, 易洪刚, 沃红梅. 帕博利珠单抗与铂类化疗方案在晚期非小细胞肺癌一线治疗中的药物经济学评价 . 药学实践与服务, 2024, 42(8): 334-340. doi: 10.12206/j.issn.2097-2024.202303023

点击查看大图

计量

文章访问数: 3641
HTML全文浏览量: 301
PDF下载量: 182
被引次数: 0

姓名
邮箱
手机号码
标题
留言内容
验证码

留言板

替吉奥治疗晚期乳腺癌的研究进展

doi: 10.3969/j.issn.1006-0111.2015.06.021

Progress on S-1 in the treatment of advanced breast cancer

计量

替吉奥治疗晚期乳腺癌的研究进展

doi: 10.3969/j.issn.1006-0111.2015.06.021

1. 福建医科大学第一临床医学院, 福建福州 350108;第二军医大学附属东方肝胆外科医院生物治疗科、病毒基因治疗实验室, 上海 200438

2. 第二军医大学附属东方肝胆外科医院生物治疗科、病毒基因治疗实验室, 上海 200438

English Abstract

Progress on S-1 in the treatment of advanced breast cancer

全文HTML

目录

留言板

替吉奥治疗晚期乳腺癌的研究进展

doi: 10.3969/j.issn.1006-0111.2015.06.021

Progress on S-1 in the treatment of advanced breast cancer

计量

出版历程

替吉奥治疗晚期乳腺癌的研究进展

doi: 10.3969/j.issn.1006-0111.2015.06.021

1. 福建医科大学第一临床医学院, 福建 福州 350108;第二军医大学附属东方肝胆外科医院生物治疗科、病毒基因治疗实验室, 上海 200438 2. 第二军医大学附属东方肝胆外科医院生物治疗科、病毒基因治疗实验室, 上海 200438

English Abstract

Progress on S-1 in the treatment of advanced breast cancer

全文HTML

目录

1. 福建医科大学第一临床医学院, 福建福州 350108;第二军医大学附属东方肝胆外科医院生物治疗科、病毒基因治疗实验室, 上海 200438

2. 第二军医大学附属东方肝胆外科医院生物治疗科、病毒基因治疗实验室, 上海 200438